23andMe

23andMe is a DNA testing technology company that enables its users to access their ancestry, genealogy, and inherited traits.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

23andMe reports strong Q1 growth, focuses on profitability and partnerships

23andMe demonstrated strong growth in customer base and subscription members, with a focus on margin expansion and revenue growth. The company faces challenges in achieving profitability but has opportunities to leverage genetics for healthcare transformation and pursue partnerships. Overall, 23andMe's performance reflects a strategic focus on growth and financial discipline.

23andMe reports Q1 revenue decline, focuses on therapeutics and AI

Despite a decrease in Q1 2023 revenue, 23andMe demonstrated strength in its therapeutics business and strategic pricing initiatives. The company faces challenges with significant workforce reduction and higher operating expenses but has opportunities in advancing immuno-oncology assets and leveraging AI advancements.

23andMe reports revenue growth and strategic initiatives for future expansion

Overall, 23andMe's Q3 performance showcased growth and innovation in both consumer and therapeutic segments. While facing challenges with increased expenses and a net loss, the company's raised full-year guidance and strategic initiatives present opportunities for future expansion and profitability.

23andMe reports revenue growth and strategic healthcare integration plans

23andMe's Q4 2023 earnings call showcased strong revenue growth, new health report offerings, and advancements in therapeutics. Despite financial projections indicating a net loss and EBITDA deficit for FY 2024, the company remains focused on expanding margins and capital efficiency. Integration of telehealth services and personalized care present promising opportunities for future growth.

23andMe reports Q1 revenue decline, eyes growth in therapeutics

23andMe navigated challenges with workforce reductions and revenue decline, focusing on margin improvement and cost discipline. The company aims to capitalize on opportunities in therapeutics and consumer businesses through strategic initiatives. With a strong cash position and guidance for improvement in adjusted EBITDA deficit, 23andMe is positioning for future growth.

23andMe reports Q2 revenue of $50M, focuses on margin expansion

23andMe's Q2 2024 performance showed revenue of $50 million with a net loss of $75 million, emphasizing margin expansion.
Strengths include new subscription offerings, FDA clearances, promising therapeutics pipeline, and data security focus.
Challenges include net losses, adjusted EBITDA deficit, and updated FY 2024 guidance reflecting uncertainties.
Opportunities lie in expanding subscription services, enhancing product offerings, and leveraging collaborations for growth.

23andMe reports Q3 revenue decline, focuses on strategic growth

23andMe faced revenue decline and increased expenses, leading to a significant net loss and revised guidance for fiscal year 2024.
Despite challenges, the company showcased strengths in strategic progress, therapeutics advancements, and extended collaborations.
Opportunities lie in margin expansion, cash flow profitability, and leveraging consumer offerings and partnerships for future growth.

23andMe reports strong revenue growth and strategic shifts for growth

23andMe showcased strong performance in membership revenue growth and advancements in research and therapeutics, despite challenges in revenue and operating expenses.
The company's strategic shift towards high-value programs and partnerships with GSK position it well for long-term growth and innovation in the genetic testing and healthcare space.
While facing challenges in cost management and revenue generation, 23andMe has opportunities to optimize operations, drive growth through new programs, and address compliance issues.
Overall, 23andMe's focus on innovation, strategic collaborations, and operational efficiency sets the stage for navigating challenges and capitalizing on growth opportunities in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

23andMe Holding Co. is a consumer genetics and research company, which engages in assisting people to access, understand, and benefit from the human genome. It operates through the Consumer and Research Services, and Therapeutics segments. The Consumer and Research Services segment consists of Personal Genome Service, Telehealth Business, and Research Services. The Therapeutics segment focuses on the genetic insights of genetic and phenotypic information. The company was founded by Anne E. Wojcickiin 2006 and is headquartered in Sunnyvale, CA.

SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Health's clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members.

23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel

NEW YORK, NY / ACCESSWIRE / June 11, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.

23andMe Holding Co (NASDAQ:ME) Jewish and Chinese Users

Savara

Vigil Neuroscience

Penny stocks are some of the most affordable investments on the market, valued at less than $5. They can hold a unique and intriguing position that can be highly profitable.

3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition

A joint investigation into a data breach at DNA testing company has been launched by UK and Canadian watchdogs.

Genetic testing firm investigated over hack

Privacy watchdogs in the U.K. and Canada have launched a joint investigation into the data breach at 23andMe last year.

UK and Canada privacy watchdogs investigating 23andMe data breach

The Canadian and British privacy authorities have launched a joint probe into a data breach at genetics testing company 23andme last year, Canada's privacy commissioner said in a statement on Monday.

Canada, UK launched joint probe into 23andMe data breach, says Canada

Provides 23andMe+ Premium members with insight into their likelihood of developing the serious mental health illness based on thousands of genetic variants Provides 23andMe+ Premium members with insight into their likelihood of developing the serious mental health illness based on thousands of genetic variants

23andMe Launches New Genetic Report on Bipolar Disorder

23andMe will partner with the Colorectal Cancer Alliance on a project to advance knowledge of colorectal cancer in the Black/African American community. Participants in the study will receive 23andMe+ Premium membership at no cost.

Why 23andMe Stock Tumbled 10% on Tuesday

– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response

23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting

Findings from 23andMe research on Parkinson's disease published in Brain Findings from 23andMe research on Parkinson's disease published in Brain

Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history

23andMe Holding Co. (NASDAQ:ME ) Q4 2024 Earnings Conference Call May 24, 2024 4:30 PM ET Company Participants Ian Cooney - Senior Director of Investor Relations Joe Selsavage - Chief Financial Officer and Chief Accounting Officer Anne Wojcicki - Chief Executive Officer and Co-Founder Jennifer Low - Head of Therapeutics Development Conference Call Participants David Lebowitz - Citi Steven Mah - TD Cowen Operator Hello, and welcome to 23andMe's Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results Conference Call. As a reminder this call is being recorded.

23andMe Holding Co. (ME) Q4 2024 Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the fourth quarter and full year of fiscal year 2024 (FY24), which ended March 31, 2024.

23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Petros Pharmaceuticals

Lemonaid Health will offer customers more affordable access to branded ED medication STENDRA that may be taken as early as ~15 minutes prior to sexual activity (100mg and 200mg strengths only) [1] Please see Important Safety Information and study design below NEW YORK, NY / ACCESSWIRE / May 14, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces the availability of all strengths of the Company's prescription erectile dysfunction (ED) medication, STENDRA (avanafil) on the telehealth platform Lemonaid Health, Inc. Lemonaid Health is a subsidiary of 23andMe Holding Co. (Nasdaq: ME), and a leading telemedicine provider. "With Lemonaid's nationwide distribution and industry leading track record of treating a significant number of ED patients across the country, we are excited to collaborate with Lemonaid Health in this expanded access initiative for STENDRA.

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe

Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activity

Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / May 10, 2024 / 23andMe (NASDAQ:ME) was hacked in December 2023, affecting approximately 7 million users of its genetic services website. According to a recently filed class complaint, hackers who infiltrated 23andMe's system were after the personal information of Jewish and Chinese customers, but the company hid that detail when notifying affected customers.

DATA BREACH- 23andMe Jewish & Chinese Consumers May be Affected

SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fourth quarter and full fiscal year 2024 (FY2024) after the market closes on Thursday, May 23, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter and year's financial results and report on business progress.

23andMe to Report Q4 and Full Year FY2024 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Potter Handy LLP, a leading consumer privacy law firm, today announced that it is representing nearly 5,000 individuals in California and Illinois impacted by the massive data breach at genetic testing company 23andMe (NASDAQ: ME). In October 2023, 23andMe revealed that an unauthorized third party had gained access to the accounts of approximately seven million customers and put the stolen data up for sale on the dark web. The compromised information included nam.

Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case

Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented

23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Like a number of companies that went public during the pandemic, 23andMe has for months been trying to manage a terrible case of SPAC-itis, an inflammation that causes plunging stock values due to the business being, as one analyst put it, not “ready for prime time.”

23andMe wants to go private. It's the latest in a line of failed SPACs

23andMe Holding Co.'s shares surged after CEO Anne Wojcicki revealed plans to potentially take the struggling DNA testing firm private. The announcement follows the company's dismal performance since going public three years ago, with shares plummeting by over 90% amid sluggish adoption of its personalized DNA services.

23andMe CEO reveals take-private plan

23andMe (NASDAQ: ME ) stock is on the move Thursday after CEO Anne Wojcicki proposed taking the consumer genetics testing company private. A filing with the Securities and Exchange Commission (SEC) reveals that Wojcicki notified members of the Board of Directors Special Committee about such a plan on April 13.

ME Stock Alert: CEO Anne Wojcicki Seeks to Save 23andMe in Take-Private Deal

23andMe (ME) chief executive Anne Wojcicki is seeking to take the DNA-testing company private less than three years after it went public, the firm said in a Securities and Exchange Commission (SEC) filing.

23andMe CEO Wojcicki Plans To Take DNA-Testing Firm Private

23andMe CEO Anne Wojcicki is considering a proposal to take the genetic testing company private

23andMe CEO Anne Wojcicki considers taking company private

SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own, as she stated in an amendment dated April 17, 2024 to her Schedule 13D filing with the Securities and Exchange Commission. Ms. Wojcicki currently owns shares constituting more than 20% of the total outstanding shares and entitling her to approximately 49% of the voting power of the total outstanding shares of 23andMe. Ms. Wojcicki also indicated in her Schedule 13D filing that she wishes to maintain control of 23andMe and, therefore, will not be willing to support any alternative transaction.

23andMe announces CEO's intention to pursue a potential take-private

Battered 23andMe Holding Co. (NASDAQ: ME), its shares driven down to penny stock levels, may disappear from the public markets completely.

News for 23andMe Stock (ME)